UB Paderborn / Katalog / Suche / in CDI

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Biologics, 2009-01, Vol.3 (default), p.419-428

2009

Link zum Volltext

Verfügbarkeit prüfen

Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

JTO clinical and research reports, 2021-08, Vol.2 (8), p.100208-100208, Article 100208

2021

Link zum Volltext

Verfügbarkeit prüfen

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Journal of clinical oncology, 2021-10, Vol.39 (28), p.3171-3181

2021

Link zum Volltext

Verfügbarkeit prüfen

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

Nature medicine, 2020-10, Vol.26 (10), p.1564-1568

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

Clinical Medicine Insights. Oncology, 2011-01, Vol.2011 (5), p.131-144

2011

Link zum Volltext

Verfügbarkeit prüfen

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)

JNCI : Journal of the National Cancer Institute, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving Chemotherapy

Journal of the National Comprehensive Cancer Network, 2023-03, Vol.21 (3), p.273

2023

Link zum Volltext

Verfügbarkeit prüfen

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Clinical lung cancer, 2021-07, Vol.22 (4), p.313-323.e1

2021

Link zum Volltext

Verfügbarkeit prüfen

New-Onset Clubbing Associated with Lung Cancer

The New England journal of medicine, 2008-09, Vol.359 (13), p.e15

2008

Link zum Volltext

Verfügbarkeit prüfen

Images in clinical medicine. New-onset clubbing associated with lung cancer

The New England journal of medicine, 2008-09, Vol.359 (13), p.e15-e15

2008

Link zum Volltext

Verfügbarkeit prüfen

Cardiac tamponade or hemopericardium are not associated with bleeding risk factors in consecutive patients hospitalized with noniatrogenic, pericardial effusions

American journal of hematology, 2010-04, Vol.85 (4), p.300-301

2010

Link zum Volltext

Verfügbarkeit prüfen

Therapy-Related Acute Myelogenous Leukemia With an 11q23/ MLL Translocation Following Adjuvant Cisplatin and Vinorelbine for Non–Small-Cell Lung Cancer

Clinical lung cancer, 2009-11, Vol.10 (6), p.438-440

2009

Link zum Volltext

Verfügbarkeit prüfen

Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9004-9004

2022

Link zum Volltext

Verfügbarkeit prüfen

SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8504-8504

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9024-9024

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9075-9075

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS4-02-GS4-02

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT013-CT013

2020

Link zum Volltext

Verfügbarkeit prüfen

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10039-10039

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program (NCORP; EAQ152) COMET trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.2008-2008

2020

Link zum Volltext

Verfügbarkeit prüfen

Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208)

JNCI : Journal of the National Cancer Institute, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.8523-8523

2019

Link zum Volltext

Verfügbarkeit prüfen

Under the Influence of Alcohol: The Effect of Ethanol and Methanol on Lipid Bilayers

Biophysical journal, 2006-02, Vol.90 (4), p.1121-1135

2006

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)

Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152)

External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving Chemotherapy

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

New-Onset Clubbing Associated with Lung Cancer

Images in clinical medicine. New-onset clubbing associated with lung cancer

Cardiac tamponade or hemopericardium are not associated with bleeding risk factors in consecutive patients hospitalized with noniatrogenic, pericardial effusions

Therapy-Related Acute Myelogenous Leukemia With an 11q23/ MLL Translocation Following Adjuvant Cisplatin and Vinorelbine for Non–Small-Cell Lung Cancer

Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A

SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC)

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A)

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A)

Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group

Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320

Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program (NCORP; EAQ152) COMET trial

Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208)

S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC)

Under the Influence of Alcohol: The Effect of Ethanol and Methanol on Lipid Bilayers

Suchergebnisse filtern